NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
Phase 2
Terminated
- Conditions
- Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00459108
- Locations
- 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
Phase 1
Completed
- Conditions
- Adenocarcinoma of the ProstateStage II Prostate CancerStage I Prostate Cancer
- Interventions
- Drug: placeboDietary Supplement: defined green tea catechin extractOther: immunohistochemistry staining methodOther: immunoenzyme techniqueOther: laboratory biomarker analysisProcedure: biopsyOther: mass spectrometryOther: high performance liquid chromatography
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00459407
- Locations
- 🇺🇸
Arizona Cancer Center - Tucson, Tucson, Arizona, United States
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1
Completed
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell LymphomaChildhood Diffuse Large Cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaChildhood Burkitt LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/Lymphoma
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT00458731
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pazopanib in Treating Patients With Recurrent Glioblastoma
Phase 2
Completed
- Conditions
- Recurrent Adult Brain TumorAdult GliosarcomaAdult GlioblastomaAdult Giant Cell Glioblastoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00459381
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- Acute Undifferentiated LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00459212
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNon-small Cell Lung CancerStage IIIB Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00459342
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Middle-School Based Primary Prevention Trial of Type 2 Diabetes
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Behavioral: integrated program of nutrition, activity, behavior, and promotion
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2020-04-30
- Target Recruit Count
- 4603
- Registration Number
- NCT00458029
- Locations
- 🇺🇸
University of California at Irvine, Irvine, California, United States
🇺🇸George Washington University Biostatistics Center, Rockville, Maryland, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
Phase 2
Completed
- Conditions
- Stage IV Lymphoepithelioma of the NasopharynxStage IV Squamous Cell Carcinoma of the NasopharynxRecurrent Lymphoepithelioma of the NasopharynxRecurrent Squamous Cell Carcinoma of the Nasopharynx
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00454142
- Locations
- 🇸🇬
Cancer Therapeutics Research Group, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
🇸🇬National Cancer Centre, Singapore, Singapore
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
- Conditions
- Gastrointestinal Carcinoid TumorIslet Cell TumorLung CancerMetastatic CancerNeoplastic Syndrome
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 408
- Registration Number
- NCT00454376
- Locations
- 🇩🇰
Aarhus Universitetshospital - Aarhus Sygehus, Aarhus, Denmark
🇩🇪Charite - Campus Charite Mitte, Berlin, Germany
🇩🇪Klinikum der Universitaet Regensburg, Regensburg, Germany
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Phase 2
Completed
- Conditions
- Gastrin-Producing Neuroendocrine TumorLung Carcinoid TumorMetastatic Digestive System Neuroendocrine Tumor G1Multiple Endocrine Neoplasia Type 1Pancreatic GlucagonomaPancreatic InsulinomaPancreatic Polypeptide TumorRecurrent Digestive System Neuroendocrine Tumor G1Recurrent Pancreatic Neuroendocrine CarcinomaRegional Digestive System Neuroendocrine Tumor G1
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00454363
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States